Molecular targeted drugs and biomarkers in NSCLC the evolving role of individualized therapy

Kalliopi Domvri, Paul Zarogoulidis*, Kaid Darwiche, Robert F. Browning, Qiang Li, J. Francis Turner, Ioannis Kioumis, Dionysios Spyratos, Konstantinos Porpodis, Antonis Papaiwannou, Theodora Tsiouda, Lutz Freitag, Konstantinos Zarogoulidis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

67 Scopus citations


Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term "maintenance" treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.

Original languageEnglish
Pages (from-to)736-754
Number of pages19
JournalJournal of Cancer
Issue number9
StatePublished - 2014
Externally publishedYes


  • Maintenance
  • Pathways
  • Targeted treatment


Dive into the research topics of 'Molecular targeted drugs and biomarkers in NSCLC the evolving role of individualized therapy'. Together they form a unique fingerprint.

Cite this